New hope to shield the brain from breast cancer spread
NCT ID NCT05323955
Summary
This study is for people with advanced HER2+ breast cancer that has spread to the brain. It tests whether adding a drug called tucatinib to their current standard treatment can better control the cancer in the brain and delay its progression there. Participants will continue their standard therapy and take tucatinib until the cancer worsens or side effects become too difficult.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
-
University of California San Francisco
San Francisco, California, 94158, United States
-
University of Michigan Health System
Ann Arbor, Michigan, 48109, United States
-
Washington University in St. Louis
St Louis, Missouri, 63130, United States
Conditions
Explore the condition pages connected to this study.